Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07562659 Capecitabine Colorectal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07562659 clinical trial report covering Capecitabine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07562490 Bevacizumab Stage III Colon Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07562490 clinical trial report covering Bevacizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07560566 Indomethacin Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07560566 clinical trial report covering Indomethacin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07562087 Lotilaner Lyme Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07562087 clinical trial report covering Lotilaner, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07560488 Bevacizumab biosimilar (Innovent Biologics) Unresectable Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07560488 clinical trial report covering Bevacizumab biosimilar (Innovent Biologics), Phase 2, endpoints, sponsor, geography, readout timing and development
Latest Hotspot
8 min read
NCT07561463 Sacituzumab tirumotecan Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07561463 clinical trial report covering Sacituzumab tirumotecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07562438 177Lu-P17-088 Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07562438 clinical trial report covering 177Lu-P17-088, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600123940 Envafolimab Biliary Tract Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600123940 clinical trial report covering Envafolimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07561294 mRNA-1982 Lyme Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07561294 clinical trial report covering mRNA-1982, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07561983 Tislelizumab Non-small cell lung cancer stage IIIB Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07561983 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07560449 Lenalidomide Plasma Cell Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07560449 clinical trial report covering Lenalidomide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07562581 Luvometinib KRAS mutant Non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07562581 clinical trial report covering Luvometinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.